Obalon Therapeutics, Inc.
5421 Avenida Encinas, Suite F
5421 Avenida Encinas, Suite F
Carlsbad, CA 92008
November 17, 2017
VIA EDGAR
The Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Heather Percival
Re: | Obalon Therapeutics, Inc. Registration Statement on Form S-3 Filed November 1, 2017 File No. 333-221264 |
Dear Ms. Percival:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, Obalon Therapeutics, Inc., a Delaware corporation (the “Registrant”), hereby requests acceleration of the effective date of the Registration Statement referred to above so that it may become effective at 5:00 p.m. Eastern Standard Time on November 17, 2017, or as soon thereafter as practicable.
We acknowledge the following:
• | should the U.S. Securities and Exchange Commission (the “Commission”) or its staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; |
• | the action of the Commission or staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
• | the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
We appreciate your assistance in this matter.
Securities and Exchange Commission
November 17, 2017
Page 2
Very truly yours,
OBALON THERAPEUTICS, INC.,
a Delaware corporation
a Delaware corporation
By: | /s/ William Plovanic |
Name: William Plovanic | |
Title: Chief Financial Officer | |
cc: B. Shayne Kennedy, Esq., Latham & Watkins LLP